Medicine for multiple sclerosis patients inhibits coronavirus - at least in a test tube

October 02, 2020

An antiviral medication which effectively inhibits replication of the coronavirus causing the COVID-19 and, at the same time, fights the immune reaction that is killing COVID-19 patients around the world.

This is the hope of a group of researchers headed by Christian Kanstrup Holm and David Olagnier who are behind a newly-published new study in the journal Nature Communications. The study shows that a drug called dimethyl fumarate (DMF), which is approved for the treatment of multiple sclerosis patients, inhibits the growth of a range of viruses in the body's cells and that this includes the coronavirus (SARS-CoV2) - at least when the researchers test it in a test tube.

"As we're doing basic research, we obviously don't know whether the drug works on infections in humans, and it's up to the infectious disease experts to test for this. However, I have to say that I'm very optimistic," says Christian Kanstrup Holm, who, like his colleague David Olagnier, is associate professor at the Department of Biomedicine at Aarhus University, Denmark.

The current research results have been underway for a while now. When the pandemic struck, Christian Kanstrup Holm and his colleagues were in the process of testing the effects of a drug which was virtually identical with a particular sclerosis medicine, namely a substance called 4-octyl-itaconate, which is used on e.g. the herpes virus, smallpox virus (vaccinia virus) and zika virus, and which is also known to lead to foetal defects - all as part of the hunt for a broad spectrum antiviral medication. And their testing succeeded beyond expectations.

"Then the coronavirus suddenly appeared, which we therefore also tested, and saw an enormous effect. The number of duplications that the coronavirus makes of itself in the body's cells were simply drastically reduced," explains Christian Kanstrup Holm.

"At the same time, the drug inhibited the immune reaction or inflammatory condition that constitutes a large portion of the actual threat for coronavirus patients. People don't just die of the virus in itself, but also of the inflammation that occurs in the lungs," he says.

When the research group saw the encouraging results with 4-octyl-itaconate, they repeated the tests with a corresponding approved product, dimethyl fumarate (DMF), which showed virtually the same inhibitory effect.

This means that the effect of dimethyl fumarate (DMF) can be tested on corona patients 'here and now', if clinicians in Denmark or abroad - and the company that holds the patent - are prepared to test it in human trials.

"You can really save a lot of time when you're testing a medication that has already been approved and tested in another context," says Christian Kanstrup Holm with reference to the statutory phases involved in getting a medication approved from scratch.

"I'd really likely to be attached to this type of clinical trial if there are infectious disease researchers who assess that the result is worth proceeding with. As a basic researcher, I have neither access to patients, nor am I qualified to conduct clinical testing," he adds.
The research results - more information

The study is a basic research study conducted in cell cultures with human lung cell lines.

Important partners from Denmark and abroad are: Jan Rehwinkel (Oxford University); Antonio Alcamí (Universidad Autónoma de Madrid); Tommy Alain (University of Ottawa); Trine Mogensen (Aarhus University and the Department of Infectious Diseases at Aarhus University Hospital); and Søren Paludan (Aarhus University).

Aarhus University

Related Infectious Disease Articles from Brightsurf:

Archaeology uncovers infectious disease spread - 4000 years ago
New bioarchaeology research from a University of Otago PhD candidate has shown how infectious diseases may have spread 4000 years ago, while highlighting the dangers of letting such diseases run rife.

Lack of continuous infectious disease pandemic research endangers responses
The coronavirus was also studied considerably less than blood borne viruses like Hepatitis B or C and H.I.V. and its research community has less prolific researchers than the other investigated diseases.

For patients with sepsis, an infectious disease expert may reduce the risk of death
When people with severe sepsis, an extreme overreaction by the body to a serious infection, come to the emergency room (ER), they require timely, expert care to prevent organ failure and even death.

Infectious disease in marine life linked to decades of ocean warming
New research shows that long-term changes in diseases in ocean species coincides with decades of widespread environmental change.

What makes some people more receptive to the idea of being vaccinated against infectious disease?
Fear, trust, and the likelihood of exposure are three leading factors that influence whether people are willing to be vaccinated against a virulent disease, according to a new study in the journal Heliyon, published by Elsevier.

Can we feed 11 billion people while preventing the spread of infectious disease?
A new article published in Nature Sustainability describes how the increase in population and the need to feed everyone will give rise to human infectious disease, a situation the authors of the paper consider 'two of the most formidable ecological and public health challenges of the 21st century.'

Climate change responsible for severe infectious disease in UK frogs
Climate change has already increased the spread and severity of a fatal disease caused by Ranavirus that infects common frogs (Rana temporaria) in the UK, according to research led by ZSL's Institute of Zoology, UCL and Queen Mary University of London published today in Global Change Biology.

New research framework may help better understand, predict infectious disease risks
University of South Florida-led research identifies individual hosts more or less likely to escalate outbreaks.

Researchers study bacterial immunity to understand infectious disease
Patients with cystic fibrosis are often infected by pseudomonas aeruginosa, a bacterium that infects the lungs and prevents breathing, often causing death.

National Academies target opioid abuse and infectious disease consequences
The National Academies of Sciences, Engineering, and Medicine today released proceedings of a March 12 workshop exploring the rise in infectious diseases accompanying opioid abuse, and possible strategies for reducing both epidemics.

Read More: Infectious Disease News and Infectious Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to